Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases

Detalhes bibliográficos
Autor(a) principal: Vargas, Ana Sofia
Data de Publicação: 2020
Outros Autores: Luís, Ângelo, Barroso, Mário, Gallardo, Eugenia, Pereira, L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.6/10447
Resumo: Authors would also like to thank to “Operação Centro-01-0145-FEDER-000019-C4-Centro de Competências em Cloud Computing,” co-financed by the CENTRO 2020 (C4 WP3.1-Data mining for systematic reviews and Meta-Analyses in Health Sciences).
id RCAP_b30069a5c43aea4a16869628f978ceff
oai_identifier_str oai:ubibliorum.ubi.pt:10400.6/10447
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening DiseasesA Systematic Review and Meta-Analysis of Clinical TrialsPsilocybinDepressionAnxietyClinical trialsSystematic reviewMeta-analysisAuthors would also like to thank to “Operação Centro-01-0145-FEDER-000019-C4-Centro de Competências em Cloud Computing,” co-financed by the CENTRO 2020 (C4 WP3.1-Data mining for systematic reviews and Meta-Analyses in Health Sciences).Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those medical conditions. The Beck Depression Inventory (BDI) was used to measure the effects in depression and the State-Trait Anxiety Inventory (STAI) was used to measure the effects in anxiety. For BDI, 11 effect sizes were considered (92 patients) and the intervention group was significantly favored (WMD = -4.589; 95% CI = -4.207 to -0.971; p-value = 0.002). For STAI-Trait, 11 effect sizes were considered (92 patients), being the intervention group significantly favored when compared to the control group (WMD = -5.906; 95% CI = -7.852 to -3.960; p-value ˂ 0.001). For STAI-State, 9 effect sizes were considered (41 patients) and the intervention group was significantly favored (WMD = -6.032; 95% CI = -8.900 to -3.164; p-value ˂ 0.001). The obtained results are promising and emphasize the importance of psilocybin translational research in the management of symptoms of depression and anxiety, since the compound may be effective in reducing symptoms of depression and anxiety in conditions that are either resistant to conventional pharmacotherapy or for which pharmacologic treatment is not yet approved. Moreover, it may be also relevant for first-line treatment, given its safety.uBibliorumVargas, Ana SofiaLuís, ÂngeloBarroso, MárioGallardo, EugeniaPereira, L.2020-09-28T08:39:47Z2020-092020-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.6/10447eng10.3390/biomedicines8090331info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:52:17Zoai:ubibliorum.ubi.pt:10400.6/10447Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:50:24.523472Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
A Systematic Review and Meta-Analysis of Clinical Trials
title Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
spellingShingle Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
Vargas, Ana Sofia
Psilocybin
Depression
Anxiety
Clinical trials
Systematic review
Meta-analysis
title_short Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
title_full Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
title_fullStr Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
title_full_unstemmed Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
title_sort Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases
author Vargas, Ana Sofia
author_facet Vargas, Ana Sofia
Luís, Ângelo
Barroso, Mário
Gallardo, Eugenia
Pereira, L.
author_role author
author2 Luís, Ângelo
Barroso, Mário
Gallardo, Eugenia
Pereira, L.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv uBibliorum
dc.contributor.author.fl_str_mv Vargas, Ana Sofia
Luís, Ângelo
Barroso, Mário
Gallardo, Eugenia
Pereira, L.
dc.subject.por.fl_str_mv Psilocybin
Depression
Anxiety
Clinical trials
Systematic review
Meta-analysis
topic Psilocybin
Depression
Anxiety
Clinical trials
Systematic review
Meta-analysis
description Authors would also like to thank to “Operação Centro-01-0145-FEDER-000019-C4-Centro de Competências em Cloud Computing,” co-financed by the CENTRO 2020 (C4 WP3.1-Data mining for systematic reviews and Meta-Analyses in Health Sciences).
publishDate 2020
dc.date.none.fl_str_mv 2020-09-28T08:39:47Z
2020-09
2020-09-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.6/10447
url http://hdl.handle.net/10400.6/10447
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.3390/biomedicines8090331
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136394655825920

Registros relacionados